Luhan Pharmachem Co., Ltd.

Luhan pharmachem Co., Ltd. supplies Tenofovir alafenamide fumarate bulk active pharmaceutical ingredient (API) to the pharmaceutical industry. Our Tenofovir alafenamide fumarate is manufactured by cGMP compliant facility. Welcome to contact us for further details including current DMF status for the product and up to date regulatory status of the manufacturing facility. We look forward to assisting you with your research and development projects.

What is Tenofovir alafenamide fumarate?

Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor and a prodrug of tenofovir. It is developed by Gilead Sciences for use in the treatment of HIV infection and chronic hepatitis B, and is applied in the form of tenofovir alafenamide fumarate (TAF). Closely related to the commonly used reverse-transcriptase inhibitor tenofovir disoproxil, TAF has greater antiviral activity and better distribution into lymphoid tissues than that agent. The FDA approved the TAF-based treatment regimen for treatment of HIV-1 in November 2015. Genvoya is the first TAF-based regimen to receive approval.

Fixed-dose combinations containing tenofovir alafenamide  Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (trade name Genvoya) — approved November 5, 2015

Emtricitabine/rilpivirine/tenofovir alafenamide (trade nameOdefsey)— approved March 1, 2016

Emtricitabine/tenofovir alafenamide (trade name Descovy)— approved April 4, 2016